Ozempic is not a weight loss drug. It is FDA-approved to treat type 2 diabetes and reduce cardiovascular and kidney risks in people with that condition. However, Ozempic contains semaglutide, the same active ingredient found in Wegovy, which is approved for weight management. This overlap is why Ozempic is so closely associated with weight loss, and why doctors sometimes prescribe it off-label for that purpose.
What Ozempic Is Approved For
The FDA has cleared Ozempic for three specific uses, all tied to type 2 diabetes. It can be prescribed alongside diet and exercise to improve blood sugar control, to reduce the risk of major cardiovascular events like heart attack and stroke in people with type 2 diabetes and heart disease, and to slow kidney decline in adults with type 2 diabetes and chronic kidney disease. Weight management does not appear anywhere on the label.
Wegovy, on the other hand, uses the same compound but is specifically approved for weight management in adults and children 12 and older, for a type of liver disease linked to metabolic dysfunction, and for cardiovascular risk reduction in adults with obesity or overweight and heart disease. The key practical difference is dosing: Ozempic tops out at 2 mg per week, while Wegovy goes up to 2.4 mg.
Why It Causes Weight Loss Anyway
Semaglutide mimics a hormone your gut naturally produces after eating called GLP-1. This hormone does several things at once: it signals your pancreas to release insulin, slows how quickly food leaves your stomach, and tells your brain you’re full. The drug is a longer-lasting version of that hormone, so its effects persist throughout the week rather than fading within minutes like the natural version does.
The appetite suppression works through multiple brain pathways simultaneously. In the brainstem, semaglutide activates receptors that enhance feelings of fullness and reduce the urge to eat. In a nearby region that lacks the protective barrier separating blood from brain tissue, it dials down the reward response to food, making eating feel less compelling. In the hypothalamus, it shifts the balance between hunger-promoting and fullness-promoting chemical signals, tipping the scales toward reduced food intake and slightly increased energy expenditure. The net result is that people on semaglutide simply want to eat less, often dramatically so.
Off-Label Prescribing for Weight Loss
Doctors can legally prescribe any FDA-approved drug for uses beyond its official label if they believe it will benefit the patient. This is called off-label prescribing, and it’s common across medicine. Many physicians prescribe Ozempic to patients without diabetes who want to lose weight, particularly when Wegovy is unavailable due to supply shortages or when cost is a factor.
The World Health Organization issued guidance in late 2025 recognizing GLP-1 drugs, including semaglutide, as appropriate for long-term obesity treatment in adults. The recommendation came with caveats: limited long-term safety data, unanswered questions about what happens when people stop the drug, high costs, and concerns about equitable access. WHO also recommended that people prescribed these medications receive structured behavioral support involving healthy diet and physical activity, noting that this combination may improve outcomes.
How Dosing Works
Ozempic is a once-weekly injection. The standard schedule starts at 0.25 mg per week for four weeks, a dose that isn’t meant to control blood sugar or produce weight loss but rather to let your body adjust and minimize side effects. After that initial period, the dose increases to 0.5 mg. If more blood sugar control is needed, a doctor may increase it further to 1 mg after at least another four weeks, with a maximum dose of 2 mg.
Common Side Effects
The most frequent side effects are gastrointestinal. Nausea affects 15% to 23% of users and is the most commonly reported complaint. Diarrhea occurs in about 8% to 14%. Constipation, bloating, burping, heartburn, and abdominal pain also show up regularly. These effects tend to be mild to moderate and are most noticeable during the early weeks or after a dose increase, which is one reason the titration schedule starts low. Fatigue, dizziness, loss of appetite, blurred vision, and reactions at the injection site round out the common side effect profile.
Insurance Coverage Depends on the Diagnosis
Most commercial insurance plans cover some or all of Ozempic’s cost when it’s prescribed for type 2 diabetes. Medicare Part D and state Medicaid programs generally do the same. Coverage for weight loss is a different story. Because weight management is not an FDA-approved use for Ozempic, insurers typically will not pay for it when prescribed off-label for that purpose. Many states don’t cover weight loss drugs through Medicaid at all, or impose special requirements before coverage begins.
This creates a practical gap: if you don’t have type 2 diabetes and your doctor prescribes Ozempic for weight loss, you may face the full out-of-pocket cost. Wegovy, being approved for weight management, has a better chance of coverage for that purpose, though policies vary widely between insurers.